Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Gilead's Truvada Slows HIV Progression Better Than GSK's Combivir, Preliminary Data Show

August 30, 2004

Gilead Sciences' once-daily combination antiretroviral drug Truvada is more effective at slowing the progression of HIV than GlaxoSmithKline's twice-daily antiretroviral Combivir, according to preliminary data released on Thursday from Gilead's Phase III clinical trial, the Raleigh News & Observer reports. The trial included 487 HIV-positive people who had never taken antiretrovirals. One group took Truvada -- a combination of Viread and Emtriva -- as well as Bristol Myers Squibb's Sustiva, generically known as efavirenz; a second group took Combivir -- which contains zidovudine and lamivudine -- and Sustiva (Ranii, Raleigh News & Observer, 8/27). Truvada succeeded in reducing HIV viral loads to fewer than 400 copies per milliliter of blood after 24 weeks in 88% of individuals on the drug, compared with 80% among the people who took Combivir (Associated Press, 8/26). The results were statistically significant, according to Gilead, Reuters reports (Reuters, 8/26). Three percent of the people who took Truvada discontinued the drug because of adverse reactions, compared with 9% of people who took Combivir. According to Eric Schmidt, an analyst at S.G. Cowen, the results of the trial were better than anticipated, the News & Observer reports. "We haven't seen the full data set," Mary Faye Dark, a spokesperson for GSK, said, adding that the study was "far from conclusive," according to the News & Observer (Raleigh News & Observer, 8/27).

Back to other news for August 30, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement